Salix Pharmaceuticals Newswire

Salix Pharmaceuticals Newswire

Comprehensive Real-Time News Feed for Salix Pharmaceuticals.

Results 1 - 20 of 71 in Salix Pharmaceuticals

  1. Salix Pharmaceuticals (SLXP) Getting Somewhat Favorable Media Coverage, Report FindsRead the original story w/Photo

    Friday Jun 23 | IntersportsWire

    Media coverage about Salix Pharmaceuticals has trended somewhat positive recently, Accern Sentiment reports. Accern identifies positive and negative news coverage by reviewing more than 20 million blog and news sources in real time.


  2. Salix Pharmaceuticals (SLXP) Getting Somewhat Favorable Press Coverage, Study ShowsRead the original story w/Photo

    Monday Jun 19 | IntersportsWire

    News articles about Salix Pharmaceuticals have trended somewhat positive this week, according to AlphaOne. The research firm, a subsidiary of Accern, identifies positive and negative press coverage by monitoring more than twenty million blog and news sources.


  3. Amazon Thanks You For Your Generosity an hour agoRead the original story w/Photo

    Friday Jun 16 | Bloomberg

    ... cash, past 10 years. As you can see, Amazon's reward is unusual. The closest rival is the takeover of Salix Pharmaceuticals Ltd., announced in 2015. Given the buyer was Valeant Pharmaceuticals International Inc., though, the less said about that one ...


  4. Enhanced Security Protocols for 2017 Belmont Stakes EntriesRead the original story w/Photo

    Tuesday Jun 6 | The Horse

    Horses running in the Belmont Stakes are subject to continuous 72-hour dedicated watch by experienced security personnel leading to post-time. In addition to the standing security protocols for horses racing in Grade I races with purses of $1 million or more, the New York State Equine Medical Director and the stewards will be made available to the media to address any incidents that might occur during races on June 10, Belmont Stakes Day.


  5. Valeant surges 4% on report that it's in talks to sell eye surgical products businessRead the original story w/Photo

    Tuesday Jun 6 | MarketWatch

    ... with nearly $30 billion in debt, which it is attempting to reduce . The company tried to sell its Salix Pharmaceuticals business to Takeda last year for $10 billion, but the deal ultimately wasn't successful. Valeant shares have risen 3.3% over the ...


  6. Salix Announces The Publication Of A Study Evaluating The Safety And...Read the original story

    May 17, 2017 | BioSpace

    Salix Announces The Publication Of A Study Evaluating The Safety And Efficacy Of UCERIS Tablets For Induction Of Remission In Patients With Active Mild To Moderate Ulcerative Colitis Refractory To Mesalamine Therapy /PRNewswire/ -- Salix Pharmaceuticals today announced the peer-reviewed publication of a study in the Journal of Crohn's & Colitis evaluating the safety and efficacy of budesonide multimatrix , which was examined for induction of remission in patients with mild to moderate ulcerative colitis refractory to baseline mesalamine therapy. Budesonide MMX or UCERIS tablets, is a prescription corticosteroid medicine used to help get mild to moderate UC under control.


  7. Redhill Biopharma: $10 Biotech Stock With Upcoming CatalystsRead the original story w/Photo

    May 16, 2017 | Seeking Alpha

    ... currently underway. They also have two approved specialty GI treatments, as well an asset licensed to Salix Pharmaceuticals which lends them a certain degree of credibility. Starting off with the company's approved assets, management expects ...


  8. Valeant Pharmaceuticals' Q1 Report Might Be the Greatest Smoke-and-Mirrors Show You'll Ever SeeRead the original story w/Photo

    May 10, 2017 | The Motley Fool

    ... this certainly appears to be the case. Continuing with sales, its branded Rx segment, which includes Salix Pharmaceuticals, a company Valeant paid $11 billion for in 2015, saw sales fall by 9% to $605 million. As a reminder, Valeant's management ...


  9. Somewhat Favorable Media Coverage Extremely Likely to Impact Salix Pharmaceuticals (SLXP) Stock PriceRead the original story w/Photo

    May 4, 2017 |

    News stories about Salix Pharmaceuticals have trended somewhat positive on Thursday, according to AlphaOne Sentiment Analysis. AlphaOne, a division of Accern, identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real-time.


  10. Shocker: Valeant Pharmaceuticals Slides Another 16% in April. Here's the Big Reason WhyRead the original story

    May 4, 2017 | Fox News

    ... Washington, and its image has been tarnished among physicians and insurers. In fact, a rumored sale of Salix Pharmaceuticals late last year for $10 billion, which Valeant acquired for roughly $11 billion in 2015, would have netted Valeant a $1 ...


  11. Salix Unveils 360-Degree Virtual Reality Experience To Evolve Medical ...Read the original story

    May 2, 2017 | BioSpace

    /PRNewswire/ -- Salix Pharmaceuticals today announced a new, interactive virtual reality (VR) tool intended to provide clinicians with an experiential learning platform that explores the causes of irritable bowel syndrome (IBS), the most common ...


  12. RedHill Biopharma to Host First Quarter 2017 Financial Results Conference Call on May 3, 2017Read the original story

    Apr 25, 2017 | P&T Community

    ... and an ongoing Phase II study for IBS-D; (iv) RHB-106 - an encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd.; (v) YELIVAA (ABC294640) - a Phase II-stage, orally-administered, first-in-class SK2 selective inhibitor targeting ...


  13. Patrick Henderson Joins Novoclem Therapeutics As Chief Financial OfficerRead the original story

    Apr 12, 2017 | BioSpace

    ... for the global S&P 500 company. Prior to LabCorp, he served as Executive Director, Finance of Salix Pharmaceuticals, a specialty pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs and medical devices ...


  14. Valeant Pharmaceuticals' Market Cap Is Now Lower Than Its Projected Full-Year EBITDARead the original story w/Photo

    Apr 13, 2017 | Fox News

    ... Bausch & Lomb sales to grow by 5% to 7% this year, and for Branded Rx sales, which includes its Salix Pharmaceuticals drugs, to increase by a modest 2% to 5%, according to its conference call. However, during the fourth quarter we saw Bausch & Lomb ...


  15. 4 Reasons Valeant Pharmaceuticals Int'l Inc. Nosedived 23% in MarchRead the original story w/Photo

    Apr 4, 2017 | Fox News

    ... same segment just delivered a 17% year-over-year sales decline in Q4. The company's acquisition of Salix Pharmaceuticals in 2015 is also looking (thus far) like a terrible decision, and its new drug distribution partnership with Walgreens Boots ...


  16. Bill Ackman's Mea Culpa Cited These 3 Factors for Valeant's DownfallRead the original story w/Photo

    Mar 31, 2017 | The Motley Fool

    ... in the annual letter to shareholders. First, Ackman blamed Valeant for significantly overpaying for Salix Pharmaceuticals. For those who may not recall, Valeant acquired Salix for $11 billion in April 2015. The allure of Salix was its line of ...


  17. After Clearing Valeant Litigation, Jaguar and Napo Pharmaceuticals ReuniteRead the original story w/Photo

    Mar 31, 2017 |

    ... the companies decided reintegration would be a smart move after Jaguar faced intense litigation with Salix Pharmaceuticals ( SLXP ) and then Valeant ( VRX ) . The litigation was over Napo's crofelemer, which is in trials for indications including ...


  18. Bill Ackman To Investors: 'Deeply And Profoundly' Sorry For The Valeant FiascoRead the original story w/Photo

    Mar 30, 2017 | Benzinga

    ... company. Ackman suggested that Valeant's downfall was due in part to its costly acquisition of Salix Pharmaceuticals, Ltd. (previously traded (NASDAQ: SLXP )) for $11.1 billion in 2015. Nevertheless, Ackman owned up to the decision to invest in ...


  19. Ackman says "profoundly sorry" for "huge mistake" in ValeantRead the original story w/Photo

    Mar 29, 2017 | Seeking Alpha

    Bill Ackman says he "deeply and profoundly" apologizes for his " huge mistake " in investing in Valeant Pharmaceuticals , which has "damaged the record of success" of his Pershing Square hedge fund. In his annual letter to investors, Ackman in part blames VRX's downfall on its $11M deal for Salix Pharmaceuticals in 2015, but he also took blame for misjudging the company's management and its aggressive strategy.


  20. Ackman Is `Profoundly' Sorry for $4 Billion Valeant `Mistake'Read the original story

    Mar 29, 2017 | The Washington Post

    Bill Ackman "deeply and profoundly" apologized for his investment in Valeant Pharmaceuticals International Inc., a "huge mistake" that cost his firm $4 billion. In his annual letter to investors in his publicly traded fund Pershing Square Holdings Ltd., Ackman in part blamed Valeant's overpaying for Salix Pharmaceuticals in 2015 for the drugmaker's downfall.